One To Watch
Alkermes
Company Overview
A fully integrated, global biopharmaceutical company headquartered in Dublin, Ireland, focused exclusively on developing and commercializing innovative medicines for psychiatric, neurological, and sleep disorders. Alkermes operates across discovery, development, and commercial stages, with approved products on market and a late-stage pipeline anchored in sleep medicine and addiction. The company trades on Nasdaq under the ticker ALKS and has undergone significant strategic transformation in recent years, divesting its oncology business and sharpening its neuroscience identity. The pending acquisition of Avadel Pharmaceuticals marks a further deepening of its commercial footprint in sleep disorders.
Headquarters and Global Presence
Alkermes is headquartered in Dublin, Ireland, and maintains significant U.S. operations. The company recently sold its development and manufacturing facility in Athlone, Ireland, to Novo Nordisk for $92.5 million, streamlining its asset base as it refocuses on neuroscience.
Founding and History
Alkermes was founded in 1987 by Michael Wall as a drug delivery-focused startup before evolving into a fully integrated biopharmaceutical company. It became publicly traded on Nasdaq and has grown through licensing, acquisitions, and internal development. In 2024, the company completed the spin-out of its oncology assets into Mural Oncology, a separately listed public company. The ongoing bid for Avadel Pharmaceuticals, announced in October 2025 and subsequently improved to fend off competing interest from Lundbeck, represents its most consequential M&A move in years.
Therapy Areas and Focus
Alkermes focuses on complex, difficult-to-treat conditions across three broad clusters: addiction (opioid and alcohol use disorders), serious mental illness (schizophrenia and bipolar I disorder), and sleep disorders (narcolepsy and idiopathic hypersomnia). The company also has early-stage programs targeting ADHD and fatigue associated with multiple sclerosis and Parkinson's disease. The strategic acquisition of Avadel is designed to expand the commercial sleep disorder franchise, which is fast becoming the company's primary growth engine.
Technology Platforms and Modalities
Alkermes applies orexin receptor pharmacology as its central scientific bet in sleep medicine, with its orexin 2 receptor (OX2R) agonist platform generating its most advanced late-stage assets. On the psychiatric side, the company has pioneered combination formulations pairing opioid antagonists with established antipsychotics to improve the safety and tolerability profiles of existing standard-of-care agents. Its commercial products — Vivitrol (naltrexone extended-release injectable) and Aristada (aripiprazole lauroxil long-acting injectable) — reflect expertise in extended-release and injectable drug delivery that underpins the platform.
Key Pipeline and Programs
Alixorexton is Alkermes' lead pipeline asset, an orexin 2 receptor agonist in development for narcolepsy. In July 2025, the company reported positive topline results from the Vibrance-1 Phase II study in narcolepsy type 1 (NT1), and followed in November 2025 with positive top-line results from Vibrance-2 in narcolepsy type 2 (NT2) — together supporting advancement to Phase III. The company has indicated these results are sufficient to move alixorexton into a pivotal program, which would position it directly against approved orexin-class competitors. Beyond narcolepsy, Alkermes is evaluating orexin 2 receptor agonists in early clinical development for ADHD and fatigue associated with MS and Parkinson's disease. ALKS 3831 (olanzapine/samidorphan), a fixed-dose combination approved as Lybalvi for schizophrenia and bipolar I disorder, represents the company's most recent successful regulatory approval and serves as a key commercial contributor. Aristada (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic, remains a core commercial asset for schizophrenia maintenance therapy.
Recent Developments
In February 2026, Alkermes completed its acquisition of Avadel Pharmaceuticals, adding the once-nightly narcolepsy treatment LUMRYZ (sodium oxybate) to a sleep-disorders portfolio that complements its in-house orexin programme. Two months later, in April 2026, the company secured FDA Breakthrough Therapy Designation for alixorexton in narcolepsy type 1 and launched the Brilliance Phase 3 programme to support a planned NDA filing.
Alkermes announced a leadership transition in 2026: founder and long-time CEO Richard Pops will step down on 31 July, with current Chief Operating Officer Blair Jackson succeeding him on 1 August. Q1 2026 results, reported on 5 May, showed continued growth in the proprietary commercial portfolio (Vivitrol, Aristada, Lybalvi) alongside the integration of LUMRYZ.
Key Personnel
Richard Pops serves as Chief Executive Officer through 31 July 2026; founder of the modern Alkermes and architect of its commercial portfolio. Blair Jackson, currently Chief Operating Officer, has been named successor and will assume the CEO role on 1 August 2026. The transition was announced as part of a planned succession ahead of the alixorexton late-stage development phase.
Strategic Partnerships
Alkermes has historically partnered with major pharma companies to co-develop and commercialize assets; Biogen previously licensed ALKS 8700 for multiple sclerosis in a collaboration where Biogen reimbursed 50% of development costs alongside an upfront payment. The pending Avadel acquisition, if completed, would bring a commercial-stage sleep disorder asset and an established infrastructure into the Alkermes portfolio. The company's manufacturing partnership ecosystem has evolved with the Athlone facility sale to Novo Nordisk, signaling a shift toward a leaner, more focused operating model.
FAQ Section
The Avadel acquisition, announced in October 2025 and subsequently improved to outcompete a rival bid from Lundbeck, is designed to expand Alkermes' commercial presence in sleep medicine ahead of anticipated Phase III data for alixorexton. Avadel is a commercial-stage company with an approved product in sleep disorders, giving Alkermes a revenue-generating base in the category it is simultaneously pursuing with its own pipeline. The deal signals sleep medicine as Alkermes' primary growth vector for the next phase of the company's development.
Narcolepsy is characterized by deficient orexin (hypocretin) signaling — particularly orexin type 1 in NT1, where neurons are destroyed, and partial deficiency in NT2. Orexin 2 receptor agonists aim to restore the wake-promoting signaling that narcolepsy patients lack, addressing the root mechanism rather than downstream symptoms. This approach has gained significant clinical validation across the sector, with alixorexton now among the leading OX2R agonists in late-stage development.
Alixorexton is a selective orexin 2 receptor agonist, aligning with the mechanistic preference for OX2R selectivity in wake promotion with a potentially differentiated safety profile versus dual orexin receptor antagonists or non-selective agonists. Positive Phase II data in both NT1 (Vibrance-1, July 2025) and NT2 (Vibrance-2, November 2025) demonstrate activity across both narcolepsy subtypes — a clinical breadth that could support a broad label. The company is advancing toward Phase III on the strength of both readouts, competing in a space that includes Takeda's oveporexton and others.
Lybalvi is the brand name for ALKS 3831 (olanzapine/samidorphan), approved by the FDA for schizophrenia and bipolar I disorder. The combination pairs the established antipsychotic olanzapine with samidorphan, an opioid receptor antagonist intended to mitigate olanzapine's well-documented weight gain liability. It received approval following positive Phase III data from the ENLIGHTEN-2 study and favorable FDA advisory committee opinion, establishing Alkermes as a commercial player in serious mental illness.
Alkermes operates across three core therapeutic clusters: addiction medicine (Vivitrol for opioid and alcohol use disorders), serious mental illness (Lybalvi and Aristada for schizophrenia and bipolar disorder), and sleep medicine (alixorexton in late-stage development for narcolepsy, plus early-stage orexin programs in ADHD, MS-related fatigue, and Parkinson's fatigue). The 2024 spin-out of Mural Oncology removed oncology from the portfolio entirely, leaving neuroscience and sleep as the company's sole focus. The Avadel acquisition would add another commercial sleep asset to anchor the third cluster.
Alkermes is a commercial-stage company with two marketed products — Vivitrol and Aristada — providing revenue while the pipeline matures. Alixorexton is transitioning from Phase II to Phase III following successful Vibrance-1 and Vibrance-2 readouts, making Phase III initiation the near-term clinical milestone. The leadership transition, with Blair Jackson succeeding Richard Pops as CEO on 1 August 2026, and the completion of the Avadel acquisition represent key corporate milestones in parallel.
Alkermes sits at a pivotal juncture, with several high-stakes developments converging in 2026 and beyond. Key watchpoints include:
Latest Alkermes News
Today's issue
| Headless Content Management with Blaze